Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of eribulin + pazopanib in advanced or recurrent malignant soft tissue tumor
jRCTs021180001Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin and pazopanib in soft tissue sarcoma (STS), sponsored by Eisai Co., Ltd. Primary endpoint: Maximum tolerated dose. Started Nov 2018; status: completed.
02
Drugs
eribulinpazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs021180001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180001.